Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440576 | 0.90 | GABRA1 (0.46) | GABRA1GABRB2ALDH1A1CYP3A4HPGD | |
| SCHEMBL2169591 | 0.88 | CYP3A4 (0.52) | GABRA1GABRB2ALDH1A1CYP3A4HPGD | |
| SCHEMBL10614861 | 0.88 | GABRA1 (0.44) | GABRA1GABRB2ALDH1A1CYP3A4HPGD | |
| SCHEMBL18245707 | 0.86 | GABRA1 (0.40) | GABRA1GABRB2ALDH1A1CYP3A4HPGD | |
| SCHEMBL10611599 | 0.85 | GABRA1 (0.70) | GABRA1GABRB2ALDH1A1CYP3A4HPGD | |
| SCHEMBL28578200 | 0.82 | ALDH1A1 (0.42) | GABRA1GABRB2ALDH1A1CYP3A4HPGD | |
| SCHEMBL14892852 | 0.82 | CA1 (0.48) | ALDH1A1CYP3A4HPGDTDP1CA1 | |
| SCHEMBL23026180 | 0.78 | CA1 (0.44) | ALDH1A1CYP3A4HPGDTDP1CA1 | |
| SCHEMBL27911783 | 0.78 | CA1 (0.44) | ALDH1A1CYP3A4HPGDTDP1CA1 | |
| SCHEMBL18245706 | 0.78 | GABRA1 (0.48) | GABRA1GABRB2ALDH1A1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849816-B | Method for treating paperboard and paper media and related treated paperboard and paper media | 巴斯夫欧洲公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-106232667-B | Polyiso-ureas | 巴斯夫欧洲公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-3296309-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2019-08-07 | — | — | EP | disclosed |
| US-20180298557-A1 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED TREATED PAPERBOARDS AND PAPER MEDIA | BASF CORPORATION | 2018-10-18 | — | — | US | disclosed |
| EP-3107946-B1 | A POLYISO-UREA | BASF SE (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-9982083-B2 | Polyiso-urea | BASF SE (DE) | 2018-05-29 | — | — | US | disclosed |
| EP-3298194-A2 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED PAPERBOARDS AND PAPER MEDIA | BASF SE (DE) | 2018-03-28 | — | — | EP | disclosed |
| EP-3296309-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit Gent (BE) | 2018-03-21 | — | — | EP | disclosed |
| EP-2877480-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2017-09-06 | — | — | EP | disclosed |
| US-20170058074-A1 | POST-MODIFIED POLYCARBODIIMIDES | BASF SE (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| EP-0920424-B1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-6194437-B1 | ANTIDEPRESSANTS; ANTICANCER AGENTS; GASTROINTESTINAL DISORDERS; COGNITION ACTIVATORS | WARNER-LAMBERT COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-0920424-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998007718-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-26 | — | — | WO | disclosed |
| US-4618682-A | ANTISECRETORY, HYPOTENSIVE AGENTS | MCNEILAB, INC. (US) | 1986-10-21 | — | — | US | disclosed |
| US-4513140-A | REACTION OF 2-IMINOIMIDAZOLIDINE WITH AN AROMATIC ISOCYANATE | MCNEILAB, INC. (US) | 1985-04-23 | — | — | US | disclosed |
| US-4046909-A | Pyrrolidylidene, piperidylidene and hexahydroazepinylidene ureas as CNS depressants | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-09-06 | — | — | US | disclosed |
| US-3998958-A | Pyrrolidylidene, piperidylidene and hexahydroazepinylidene ureas as CNS depressants | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | GABRA1 3246/4885GABRB2 3852/4885ALDH1A1 2549/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | GABRA1 3246/4885GABRB2 3852/4885ALDH1A1 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.